PMID- 36042519
OWN - NLM
STAT- MEDLINE
DCOM- 20220902
LR  - 20220929
IS  - 1478-811X (Electronic)
IS  - 1478-811X (Linking)
VI  - 20
IP  - 1
DP  - 2022 Aug 30
TI  - HK2: a potential regulator of osteoarthritis via glycolytic and non-glycolytic 
      pathways.
PG  - 132
LID - 10.1186/s12964-022-00943-y [doi]
LID - 132
AB  - Osteoarthritis (OA) is an age-related chronic degenerative joint disease where 
      the main characteristics include progressive degeneration of cartilage, varying 
      degrees of synovitis, and periarticular osteogenesis. However, the underlying 
      factors involved in OA pathogenesis remain elusive which has resulted in poor 
      clinical treatment effect. Recently, glucose metabolism changes provide a new 
      perspective on the pathogenesis of OA. Under the stimulation of external 
      environment, the metabolic pathway of chondrocytes tends to change from oxidative 
      phosphorylation (OXPHOS) to aerobic glycolysis. Previous studies have 
      demonstrated that glycolysis of synovial tissue is increased in OA. The 
      hexokinase (HK) is the first rate limiting enzyme in aerobic glycolysis, 
      participating and catalyzing the main pathway of glucose utilization. An isoform 
      of HKs, HK2 is considered to be a key regulator of glucose metabolism, promotes 
      the transformation of glycolysis from OXPHOS to aerobic glycolysis. Moreover, the 
      expression level of HK2 in OA synovial tissue (FLS) was higher than that in 
      control group, which indicated the potential therapeutic effect of HK2 in OA. 
      However, there is no summary to help us understand the potential therapeutic role 
      of glucose metabolism in OA. Therefore, this review focuses on the properties of 
      HK2 and existing research concerning HK2 and OA. We also highlight the potential 
      role and mechanism of HK2 in OA. Video abstract.
CI  - (c) 2022. The Author(s).
FAU - Bao, Chuncha
AU  - Bao C
AD  - Department of Rehabilitation Medicine, West China Hospital, Sichuan University, 
      Chengdu, 610041, Sichuan, People's Republic of China.
AD  - Sichuan Key Laboratory of Rehabilitation Medicine, West China Hospital, Sichuan 
      University, Chengdu, People's Republic of China.
FAU - Zhu, Siyi
AU  - Zhu S
AD  - Department of Rehabilitation Medicine, West China Hospital, Sichuan University, 
      Chengdu, 610041, Sichuan, People's Republic of China. hxkfzsy@scu.edu.cn.
AD  - Sichuan Key Laboratory of Rehabilitation Medicine, West China Hospital, Sichuan 
      University, Chengdu, People's Republic of China. hxkfzsy@scu.edu.cn.
FAU - Song, Kangping
AU  - Song K
AD  - Department of Rehabilitation Medicine, West China Hospital, Sichuan University, 
      Chengdu, 610041, Sichuan, People's Republic of China.
AD  - Sichuan Key Laboratory of Rehabilitation Medicine, West China Hospital, Sichuan 
      University, Chengdu, People's Republic of China.
FAU - He, Chengqi
AU  - He C
AD  - Department of Rehabilitation Medicine, West China Hospital, Sichuan University, 
      Chengdu, 610041, Sichuan, People's Republic of China. hxkfhcq2015@126.com.
AD  - Sichuan Key Laboratory of Rehabilitation Medicine, West China Hospital, Sichuan 
      University, Chengdu, People's Republic of China. hxkfhcq2015@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Video-Audio Media
DEP - 20220830
PL  - England
TA  - Cell Commun Signal
JT  - Cell communication and signaling : CCS
JID - 101170464
RN  - EC 2.7.1.1 (HK2 protein, human)
RN  - EC 2.7.1.1 (Hexokinase)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Glucose/metabolism
MH  - *Glycolysis
MH  - Hexokinase/*metabolism
MH  - Humans
MH  - *Osteoarthritis/metabolism
MH  - Synovial Membrane/pathology
PMC - PMC9426234
OTO - NOTNLM
OT  - Chondrocyte
OT  - Glycolysis
OT  - Hexokinase 2
OT  - Metabolism
OT  - Osteoarthritis
COIS- The authors declare that they have no competing interests.
EDAT- 2022/08/31 06:00
MHDA- 2022/09/03 06:00
PMCR- 2022/08/30
CRDT- 2022/08/30 23:49
PHST- 2022/01/26 00:00 [received]
PHST- 2022/05/20 00:00 [accepted]
PHST- 2022/08/30 23:49 [entrez]
PHST- 2022/08/31 06:00 [pubmed]
PHST- 2022/09/03 06:00 [medline]
PHST- 2022/08/30 00:00 [pmc-release]
AID - 10.1186/s12964-022-00943-y [pii]
AID - 943 [pii]
AID - 10.1186/s12964-022-00943-y [doi]
PST - epublish
SO  - Cell Commun Signal. 2022 Aug 30;20(1):132. doi: 10.1186/s12964-022-00943-y.